Stonking Small Caps: compelling value
The founder of this fast-growing technology group has an impressive track record, having already developed and sold a sizeable high-profile business. While half year results covered here are in-line with previously revised forecasts, the loss of a large contract has cast a shadow over the shares. Is this a sign of more trouble ahead or does it present an interesting buying opportunity for the long-term investor in an innovative UK company?
This fast-growing company’s systems and technology are setting new standards in reliability and are years ahead of competitors, attracting a growing number of government departments as customers, which had been delivering very strong revenue growth. The attractive growth prospects, high operating margins and return on equity and excellent cash flow means the shares deservedly command a premium rating, which is no longer the case, as you will discover here. While the current focus is on the criminal justice market, there is also considerable potential in the health and care markets, where the technology was first conceived. It's also increasingly rare to come…